Related coverage linked through entity extraction aliases.
Feb 13, 2026
A study published in JAMA Cardiology found that semaglutide would be cost-effective for secondary cardiovascular disease prevention in U.S. adults with overweight or obesity at an 18% price reduction or at the current cash price of $5,988 annually.
Feb 13, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and multiple partnerships to expand its drug pipeline beyond its blockbuster GLP-1 franchise into cell and genetic therapies.
Feb 13, 2026
Bio-Rad Laboratories reported Q4 2025 revenue of $693.2 million, up 3.9%, driven by Clinical Diagnostics growth, while Life Science sales declined 2.6% due to constrained academic and biotech funding. Gross and operating margins fell below expectations.
Apr 21, 2025
Orforglipron, an oral non-peptide GLP-1R partial agonist developed by Chugai and Eli Lilly, has reported positive Phase III data for obesity and type 2 diabetes, representing a shift from injectable peptides to oral small molecules in the GLP-1R space.
Dec 12, 2025
Eli Lilly reported positive Phase 3 results for retatrutide showing up to 71.2 lbs average weight loss, while stockpiling $1.5 billion of oral drug orforglipron ahead of anticipated FDA approval in April 2026.
Feb 10, 2026
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
